Etiological profile and clinical characteristics in fulminant hepatic failure in North India
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20191398Keywords:
Acute liver failure, Fulminant hepatic failure, Viral hepatitis, Hepatitis E virus, Drug-induced liver failureAbstract
Background: Acute liver failure (ALF) is a rare but severe, life-threatening, multisystemic medical emergency. ALF of duration <8 weeks in a patient is considered as fulminant hepatic failure (FHF). Its rapid progression and high mortality demand early diagnosis and expert management. Clinical and etiological profile varies with geographical area and time. The objective of this prospective study was to determine the clinical characteristics and etiological profile of FHF.
Methods: A total of eighty consecutive patients with a diagnosis of FHF were included in the study. The variables evaluated were demographic, signs and symptoms, biochemical parameters (bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), internal normalization ratio (INR) etc.) and etiological profile.
Results: Most of the patients were <35 years of age and males. Viral hepatitis 35 (43.8%) was the most common cause of FHF but the majority of the patients 25 (31.2%) had undetermined etiology. Among viral causes, acute hepatitis E was most common followed by hepatitis B and A. Drug or toxic induced liver failure (18.8%) also contributed a significant proportion of cases. The three groups (viral, drug-induced and indeterminate) were comparable for the various baseline characteristics (bilirubin, alanine aminotransferase, INR, creatinine, albumin, grade of encephalopathy, MELD score etc.).
Conclusions: Like the rest of India, viral hepatitis was the common cause of FHF but the majority of the patients 25 (31.2%) had undetermined etiology. Our study highlights the differences in the profile of FHF from other earlier studies in India and the west. Each different etiology leads to a similar final common pathway. Trying to determine etiology is essential, however, as outcomes and the use of antidotes depend on the identification of the causative process.
References
Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102:2459-63.
Brandsaeter B, Hockerstedt K, Friman S. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation—12 years experience in the Nordic countries. Liver Transpl. 2002;8:1055–62.
Escorsell A, Mas A. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl. 2007;13;89–95.
Hoofnagle JH, Carithers RL, Shapiro C. Fulminant hepatic failure:summary of a workshop. Hepatology. 1995;21:240-52.
Rockville. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2007.
Trey C, Davidson CS. The management of fulminant hepatic failure. Progress in liver disease; Prog Liver Dis. 1970;3:282-98.
Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy:a controlled, double-blind clinical trial. Am J Dig Dis. 1978;23(5):398-406.
O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–5.
O’Grady JG, Williams R. Classification of acute liver failure. Lancet. 1993;342(8873):743.
Ostapowicz G, Fontana RJ, Schiodt FV. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947–954.
Acharya SK, Dasarathy S, Kumer TL, Sushma S, Prasanna KS, Tandon A, et al. Fulminant hepatitis in tropical population:clinical course, cause, and early predictors of outcome. Hepatology. 1996;23:1448-55.
Tibbs C, Williams R. Viral causes and management of acute liver failure. J Hepatol. 1995;22(Suppl. 1):68-73.
Fagan EA, Williams R. Fulminant viral hepatitis. Br Med Bull. 1990;46:462-80.
Khuroo MS, Kamili S. Aetiology and prognostic factors in acute liver failure in India. J Viral Hepat. 2003;10:224–31.
Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38:33–8.
Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, Khor C, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007;27:465–74.
Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731–9.
Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury:an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–21.
Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–9.
Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries:a French population-based study. Hepatology. 2002;36:451–5.
Bansal J, He J, Yarbough PO. Hepatitis E virus infection in eastern India. Am J Trop Med Hyg. 1998;59:258-60.
Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. Semin Liver Dis. 2003;23:227–37.
Wei G, Kalaitzakis E, Bergquist A, Bjornsson E. Long-term follow up of patients with acute liver failure of indeterminate aetiology. Scand J Gastroenterol. 2008;43:984–91.
Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure:definitions and causes. Semin Liver Dis. 1986;6:97-106.
Rolando N, Harvey F, Brahm J, Howard JP, Alexander G, Gimson A, et al. Prospective study of bacterial infections in acute liver failure:an analysis of fifty patients. Hepatology. 1990;11:49–53.
Nabi T, Nabi S, Rafiq N, Shah A. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure:A prospective study. Saudi J Gastroenterol. 2017;23(3):169–75.
Lee WM, Sorrell MF. Developing a world view toward acute liver failure. Hepatology. 1996;24:270–1.
Das AK, Begum T, Kar P, Dutta A. Profile of Acute liver failure from North-east India and its differences from other parts of country. Eurosian J Hepato-Gastroenterol. 2016;6(2):111–5.
O’Grady LG, Alexadner GJM, Hayllar K, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–45.
Khuroo MS, Duermeyer W, Zargar SA, Ahanger MA, Shah MA. Acute sporadic hepatitis in India. Am J Epidemiol. 1983:118:360–4.
Ramaliingaswami V, Purcell RH. Waterborne Non-A, non-B hepatitis. Lancet. 1988;1:571–3.
Khuroo MS, Rustgi VK, Dawson GJ, Mushahwar IK, Yattoo GN, Kamili S, et al. Spectrum of hepatitis E virus in India. J Med Virol. 1994;43:281–6.
Farci P, Alter H, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med. 1997;335:631–4.
Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan:a multicentric study. J Gastroenterol Hepatol. 1991;6:159–64.
Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol:analysis of instances of therapeutic misadventure. Hepatology. 1995;22:588–97.
Sherlock S, Dooley J. Diseases of the liver and biliary system, 9th edn. Oxford: Blackwell Scientific Publications, 1993.
Datta DV, Khuroo MS, Mattocks AR, Aikat BK, Chhuttain PN. Herbal medicines and veno-occlusive disease in India. Postgraduate Medical J. 1978;54:511–5.
James LP, Alonso EM, Hynan LS, Hinson JA, Davern TJ, Lee WM, et al. Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics 2006;118:676–81.
Squires RH, Dhawan A, Alonso E, Narkewicz MR., Shneider BL, Baez NR, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure:A placebo-controlled clinical trial. Hepatology. 2013;57(4):1542–9.
Khuroo MS, Datta DV. Budd–Chiari syndrome following pregnancy. Report of 16 cases with roentgenologic hemodynamic and histologic studies of the hepatic outflow tract. Am J Med. 1980;68:113–21.
